Leonteq Securities AG Makes New Investment in CRISPR Therapeutics AG $CRSP
Leonteq Securities AG recently acquired a new stake in CRISPR Therapeutics AG, purchasing 22,020 shares valued at approximately $1.155 million during the fourth quarter. This move highlights ongoing significant institutional ownership, with 69.20% of the company's stock held by institutions. Analyst sentiment for CRISPR Therapeutics remains generally positive, rating it a "Moderate Buy" with a consensus price target of $65.47, despite some insider selling activities.
CRISPR Therapeutics AG $CRSP Shares Bought by Northwestern Mutual Wealth Management Co.
Northwestern Mutual Wealth Management Co. significantly increased its stake in CRISPR Therapeutics AG (CRSP) during the fourth quarter, boosting its holdings by over 2,300% to 230,305 shares valued at approximately $12.1 million. Other institutional investors also expanded their positions, with institutional ownership of CRSP reaching 69.2%. Analysts generally maintain a "Moderate Buy" rating for CRSP, with an average price target of $65.47, despite recent insider share sales.
Crispr Therapeutics remains a Buy with strong pipeline and cash despite slow Casgevy uptake.
Crispr Therapeutics is rated a Buy due to its robust drug pipeline, careful capital management, and a significant partnership with Vertex, even considering the slow adoption of its Casgevy therapy. While Casgevy's market growth is currently limited by strict preconditioning requirements, future treatments and gentler regimens are expected to broaden its reach. The company boasts a diverse pipeline, including therapies for cardiovascular disease, diabetes, and CAR-T, with crucial clinical results anticipated through 2026, and a strong financial runway of 5-6 years thanks to $1.65 billion in net cash and disciplined R&D spending.
Bernstein Raises its Price Target on CRISPR Therapeutics (CRSP)
Bernstein increased its price target for CRISPR Therapeutics AG (NASDAQ:CRSP) to $56 from $50, while BofA reduced its target to $83 from $86. The adjustments follow strong biotech sector performance and CRISPR's first-quarter revenue report of $1.4M, with management highlighting progress in gene-editing programs and a strengthened balance sheet.
CRISPR Therapeutics stock (CH0334081137): gene-editing pioneer ahead of next earnings test
CRISPR Therapeutics, a gene-editing pioneer, is gearing up for its next earnings report with investors keenly watching its progress in gene-editing therapies and U.S. regulatory milestones. The company's business model relies heavily on collaborations and a robust pipeline focused on severe diseases like sickle cell, with future revenue potential tied to regulatory approvals and successful commercialization. Despite ongoing net losses due to significant R&D investment, the company's long-term value for U.S. investors lies in its ability to navigate complex regulatory landscapes and successfully bring its innovative CRISPR/Cas9-based treatments to market.
CRISPR Therapeutics AG (CRSP) is attracting investor attention: Here is what you should know
This article from MSN notes that CRISPR Therapeutics AG (CRSP) is currently attracting investor attention. It suggests that readers should be aware of this interest, although no specific details about why CRSP is gaining attention are provided in this extracted content.
Is CRISPR (CRSP) Quietly Rewriting Its Gene‑Editing Priorities After Narrower Losses and Casgevy Progress?
CRISPR Therapeutics (CRSP) reported narrower first-quarter 2026 losses and discussed its gene-editing pipeline and Casgevy's expansion at a recent conference. The company's investment narrative centers on Casgevy's potential as a durable franchise while also navigating funding needs and avoiding painful trade-offs in its broader pipeline development. The reliance on Casgevy raises a unique risk while analysts offer varied fair value estimates for the stock.
Is CRISPR (CRSP) Quietly Rewriting Its Gene‑Editing Priorities After Narrower Losses and Casgevy Progress?
CRISPR Therapeutics (CRSP) recently reported narrower first-quarter 2026 losses and discussed ongoing progress with Casgevy and its broader gene-editing pipeline. The company's focus on expanding Casgevy's potential is shaping its investment narrative, especially given its reliance on a single approved product. While the shares may still be trading above fair value, analysts see upside, and investors are urged to consider multiple viewpoints before forming their conviction.
CRISPR Therapeutics Enters 'Second Phase' as CASGEVY Momentum Builds, Pipeline Data Looms
CRISPR Therapeutics is entering a "second phase," shifting focus from the commercialization of CASGEVY to a broader pipeline of therapies. CEO Sam Kulkarni highlighted the growing momentum of CASGEVY's launch, with over 500 patient initiations, and expects data from six new programs in cardiovascular, autoimmune, oncology, and rare diseases within the next 12-18 months. The company is also pursuing potential tailwinds for CASGEVY, including a pediatric label expansion and "gentler conditioning" approaches.
CRISPR Therapeutics AG Trade Ideas — SWB:1CG
This article compiles various trade ideas and analyses for CRISPR Therapeutics AG (SWB:1CG). Traders offer diverse perspectives ranging from bullish outlooks based on technical patterns and upcoming earnings to bearish predictions due to market corrections and short-term resistance. The content also delves into a comprehensive analysis of CRSP's financials, pipeline, and valuation, highlighting its collaboration with Vertex Pharmaceuticals and Cathie Wood's investment interest.
CRISPR Therapeutics Enters 'Second Phase' as CASGEVY Momentum Builds, Pipeline Data Looms
CRISPR Therapeutics is entering a "second phase" with CEO Sam Kulkarni highlighting the commercial momentum of CASGEVY and a robust pipeline with six assets expected to generate data within the next 12 to 18 months. The company is expanding its focus beyond CASGEVY to include cardiovascular, autoimmune, oncology, and rare disease programs, with potential tailwinds like pediatric label expansion and favorable reimbursement for CASGEVY. Kulkarni also discussed progress in cardiovascular programs, including CTX310 and CTX340, and the advancement of zugo-cel in both autoimmune diseases and oncology.
Orbis, Allan Gray report 6.3% stake in CRISPR Therapeutics (CRSP)
Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd have filed an amended Schedule 13G/A, revealing a combined 6.3% beneficial ownership in CRISPR Therapeutics (CRSP). The filing shows Orbis holds 6,090,194 shares and Allan Gray holds 15,817 shares, both with sole voting and dispositive power. Both entities are classified as non-U.S. institutions equivalent to investment advisers.
CRISPR Therapeutics AG (CRSP) is attracting investor attention: Here is what you should know
This article highlights CRISPR Therapeutics AG (CRSP) as a company garnering investor attention. It suggests that investors should be aware of key information surrounding CRSP, implying potential developments or financial movements relevant to the company.
Capital World Investors discloses 5.1% stake in CRSP (4.93M shares)
Capital World Investors has reported a 5.1% stake in CRISPR Therapeutics AG (CRSP), amounting to 4,929,428 shares of Common Stock. This disclosure was made via a Schedule 13G filing, indicating that Capital World Investors holds sole voting power over 4,897,705 shares and sole dispositive power over all 4,929,428 shares. The beneficial ownership stake was reported as of March 31, 2026.
CRISPR Therapeutics stock (CH0334081137): Bernstein raises price target amid gene-editing momentum
Bernstein has raised its price target for CRISPR Therapeutics (CH0334081137) to $56, maintaining its rating and reflecting confidence in the gene-editing platform developer's therapeutic pipeline. CRISPR Therapeutics, specializing in CRISPR/Cas9 gene-editing therapies, is watched by investors for its potential in precision medicine, with its financial trajectory dependent on advancing candidates through regulatory approval and commercialization. The company's stock traded at $52.75 USD on May 14, 2026, on Nasdaq.
Vanguard Group Inc. Reduces Stock Position in CRISPR Therapeutics AG $CRSP
Vanguard Group Inc. decreased its stake in CRISPR Therapeutics AG by 4.1% in the fourth quarter, selling 96,251 shares and retaining 2.27 million shares valued at approximately $119 million. Despite this, institutional investors collectively own 69.2% of the company's stock, with several hedge funds increasing their positions. The stock currently holds a "Moderate Buy" consensus rating from analysts with an average target price of $66.06, although company insiders have been net sellers in the last 90 days.
A Look At CRISPR Therapeutics (CRSP) Valuation As CASGEVY Progress And New Funding Lift Investor Interest
CRISPR Therapeutics (CRSP) is actively discussed for its valuation following Q1 2026 results, CASGEVY commercialization, and new funding. Despite short-term share price momentum and a discounted cash flow (DCF) model suggesting undervaluation at $190.29 compared to its current price of $54.83, the stock trades at a higher P/B ratio (2.9x) than the US Biotechs industry average (2.4x). This provides mixed signals for investors, highlighting both potential future growth and inherent execution risks.
1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist?
A top Wall Street analyst believes CRISPR Therapeutics (CRSP) could more than double, with Piper Sandler's Edward Tenthoff setting a $110 price target. This bullish sentiment is fueled by potential catalysts like upcoming clinical trial data readouts for candidates such as the anticoagulant CTX611 and potential expansion of its approved product, Casgevy, to younger patients. While the stock carries risk due to its volatility and reliance on clinical success, its innovative gene-editing platform and robust pipeline, backed by $2.4 billion in cash, suggest promising long-term growth for investors with a high risk tolerance.
The Bull Case For CRISPR Therapeutics (CRSP) Could Change Following CASGEVY Uptake And New Capital Raise – Learn Why
CRISPR Therapeutics recently reported Q1 2026 results, showing continued commercial uptake of CASGEVY and progress in its gene editing pipeline. The company also secured $600 million in convertible notes, bolstering its balance sheet but raising dilution concerns. While CASGEVY's success and pipeline advancements are crucial, a wide range of fair value estimates highlights investor uncertainty regarding the company's long-term potential and current cash burn.
CRISPR Therapeutics' Q1 loss wider than expected, sales miss estimates
CRISPR Therapeutics (CRSP) reported a wider-than-expected loss in Q1 2026, with sales also missing analyst estimates. The biotechnology company posted a loss of $1.90 per share against an estimated loss of $1.76 per share, and revenue of $0.20 million, significantly below the expected $4.18 million. This financial performance indicates challenges for the gene-editing company in the reported quarter despite its innovative research.
Nwam LLC Has $3.38 Million Position in CRISPR Therapeutics AG $CRSP
Nwam LLC reduced its stake in CRISPR Therapeutics AG by 39.2% in the fourth quarter, holding 61,843 shares valued at approximately $3.38 million. Despite mixed but generally constructive analyst sentiment, including a "Buy" rating from Piper Sandler and raised earnings estimates from some firms, CRISPR Therapeutics is still anticipated to report losses. The company's financial profile indicates a high-risk pre-profitability stage, with a recent quarterly EPS loss of $1.28 on minimal revenue.
Number of shareholders of CRISPR Therapeutics AG Shs Thailand Depositary Receipts Repr 1 Sh – SET:CRSP03
This article focuses on the number of shareholders for CRISPR Therapeutics AG Shs Thailand Depositary Receipts Repr 1 Sh (SET:CRSP03). It presents a table for period, value, change, and change percentage of shareholders, although the table content itself is not filled in the provided text. The article is part of a financial data service, indicating it provides specific market information related to this stock.
The Bull Case For CRISPR Therapeutics (CRSP) Could Change Following CASGEVY Uptake And New Capital Raise – Learn Why
CRISPR Therapeutics (CRSP) recently reported Q1 2026 results including $1.46 million in revenue and a $122.93 million net loss, alongside progress in CASGEVY uptake and its broader pipeline. The company secured an additional $600 million through convertible senior notes, extending its financial runway. Investors are now focused on CASGEVY's continued commercial success and upcoming pipeline updates as key drivers for the stock's future valuation and to justify the ongoing investments.
The Bull Case For CRISPR Therapeutics (CRSP) Could Change Following CASGEVY Uptake And New Capital Raise – Learn Why
CRISPR Therapeutics reported Q1 2026 results with $1.46 million in revenue and a $122.93 million net loss, alongside continued commercial uptake of CASGEVY and progress in its gene-editing pipeline. The company also secured $600 million in Convertible Senior Notes, extending its financial runway. This article explores how CASGEVY’s early success and pipeline developments shape the investment outlook for CRSP, while also highlighting the inherent risks and diverse analyst opinions on its valuation.
CRISPR Therapeutics (NASDAQ:CRSP) Upgraded to Hold at Wall Street Zen
Wall Street Zen has upgraded CRISPR Therapeutics (CRSP) from "sell" to "hold," contributing to a mixed but generally cautious outlook from analysts. Despite some recent positive revisions on earnings estimates and a "Moderate Buy" consensus rating with a $65.94 target, the company remains a loss-making biotech with recent insider share sales. CRSP reported a per-share loss of $1.28 last quarter and analysts expect an full-year EPS of -5.07, indicating it is still a speculative, pre-profitability investment.
CRISPR Therapeutics Expands Pipeline As CASGEVY Grows And Cash Pile Rises
CRISPR Therapeutics is expanding its pipeline by advancing its CAR-T program, zugo-cel, into new autoimmune disease indications and progressing multiple in vivo gene editing programs. Its gene-editing therapy, CASGEVY, is gaining commercial traction, and the company plans to extend its label to younger pediatric patients. A recent convertible notes offering has significantly increased its cash reserves, funding this broader clinical development as CRISPR Therapeutics transitions from R&D to wider product launches and potential future cash flow generation.
CRISPR Therapeutics AG (CRSP) reports Q1 loss, lags revenue estimates
CRISPR Therapeutics AG (CRSP) reported a wider loss than expected in the first quarter, with revenue also falling short of analyst estimates. The company posted a loss of $1.56 per share, exceeding the Zacks Consensus Estimate of a $1.48 loss, and recorded revenue of $93.7 million, missing the consensus by 2.37%.
Crispr Therapeutics AG (CRSP) Gets a Buy from Piper Sandler
Piper Sandler reiterated a Buy rating for Crispr Therapeutics AG (CRSP) with a $110.00 price target, based on an analyst report from Edward Tenthoff. This follows Crispr Therapeutics AG reporting a quarterly revenue of $864 thousand and a GAAP net loss of $130.61 million for the quarter ending December 31. Needham also issued a Buy rating, while RBC Capital maintained a Hold rating.
CRISPR Therapeutics AG (CRSP) reports Q1 loss, lags revenue estimates
CRISPR Therapeutics AG (CRSP) reported a loss for its first quarter, failing to meet revenue estimates. This financial update provides key information on the company's recent performance.
CRISPR Therapeutics' Q1 Loss Wider Than Expected, Sales Miss Estimates
CRISPR Therapeutics (CRSP) reported a wider-than-expected loss of $1.28 per share in Q1 2026, missing revenue estimates with $1.46 million. Despite the financial miss, the company's stock is up 2% year to date, and its gene therapy, Casgevy, with partner Vertex Pharmaceuticals, shows strong sales momentum. CRISPR is also expanding its pipeline with new regulatory filings for Casgevy, advancing investigational CAR-T cell therapy zugo-cel, and progressing several in-vivo candidates.
CRISPR Therapeutics (NasdaqGM:CRSP) Stock Forecast & Analyst Predictions
CRISPR Therapeutics (CRSP) is forecast to grow earnings and revenue significantly, with analysts providing a consensus price target of $86.78. The company's gene-editing therapy, Casgevy, has received regulatory approvals and is seen as a key growth driver, despite a slow commercial launch. CRISPR is also advancing a broad pipeline, including therapies for autoimmune diseases and cardiovascular conditions, supported by strong liquidity.
CRISPR Therapeutics AG (CRSP) reports Q1 loss, lags revenue estimates
CRISPR Therapeutics AG (CRSP) announced its Q1 earnings, reporting a loss per share that was narrower than anticipated. However, the company's revenue for the quarter fell short of Wall Street estimates. This mixed financial performance indicates challenges in revenue generation despite better-than-expected cost control.
CRISPR Therapeutics (NASDAQ:CRSP) Posts Earnings Results, Misses Estimates By $0.06 EPS
CRISPR Therapeutics (NASDAQ:CRSP) announced its earnings results, reporting an adjusted EPS of -$1.28, missing analyst estimates by $0.06. The company also reported revenue of $1.46 million against expectations of $6.06 million, resulting in severely negative net margins and return on equity. Despite the earnings miss and recent insider selling, CRSP stock saw a 3.8% increase in midday trading, and analysts maintain a "Moderate Buy" rating with an average price target of $64.53.
CRISPR Therapeutics AG 1Q 2026: Revenue $1.458M, EPS $(1.28) — 10-Q Summary
CRISPR Therapeutics AG (CRSP) reported its first-quarter 2026 financial results, with revenue reaching $1.458 million and a diluted loss per share of $(1.28). This represents a narrowing of net loss and an improvement in diluted EPS compared to the same quarter in the previous year. The company highlighted ongoing progress in product approvals, pipeline development, in vivo and delivery advances, CAR-T and regenerative programs, and strategic partnerships.
Earnings Flash (CRSP) CRISPR Therapeutics AG Reports Q1 Revenue $1.5M, vs. FactSet Est of $6.1M
CRISPR Therapeutics AG (CRSP) reported Q1 revenue of $1.5 million, significantly missing FactSet's estimate of $6.1 million. The company is a Switzerland-based gene editing firm focused on developing CRISPR/Cas9-based therapeutics. This revenue report comes alongside other recent news, including insider stock sales and convertible notes offerings.
CASGEVY revenue and cash build at CRISPR Therapeutics (NASDAQ: CRSP) in Q1 2026
CRISPR Therapeutics (CRSP) reported its Q1 2026 financial results, highlighting $43 million in revenue from its gene-edited therapy CASGEVY. The company's cash position significantly improved to $2.44 billion due to convertible senior notes, while its net loss narrowed to $122.9 million. CRISPR Therapeutics also provided updates on its broad pipeline, including progress in liver editing, autoimmune disease, immuno-oncology, siRNA programs, and regenerative medicine.
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
CRISPR Therapeutics reported its first quarter 2026 financial results, with CASGEVY generating $43 million in revenue and expanding its global reach. The company highlighted significant progress across its pipeline, including advancing in vivo liver-directed programs and expanding zugo-cel into new autoimmune indications. With a strong financial position, CRISPR Therapeutics anticipates 2026 to be a pivotal year marked by multiple upcoming milestones in gene editing and cell therapy.
Assessing CRISPR Therapeutics (CRSP) Valuation After Casgevy Approval And CAR T Pipeline Progress
CRISPR Therapeutics (CRSP) has garnered attention following regulatory approval for its gene editing therapy, Casgevy, and progress in its CAR T pipeline. While its Price-to-Book ratio of 2.6x suggests reasonable value compared to peers, a Discounted Cash Flow (DCF) model indicates the stock, currently at $51.63, may be significantly undervalued at 72% below an estimated fair value of $184.66. Investors are encouraged to weigh the upside potential against ongoing risks such as the company's loss-making profile.
CRISPR Therapeutics (CRSP) Projected to Post Quarterly Earnings on Monday
CRISPR Therapeutics (CRSP) is expected to announce its Q1 2026 earnings before market open on Monday, May 11th, with analysts projecting an EPS of ($1.2227) and revenue of $6.064 million. The company missed previous earnings estimates, reporting ($1.37) EPS against a ($1.15) expectation, and experienced a significant year-over-year revenue decrease. Insider selling has been noted, while institutional investors, including ARK and GSK, hold substantial stakes, contributing to a "Moderate Buy" consensus rating and a $64.53 price target.
Pictet Asset Management Holding SA Sells 25,129 Shares of CRISPR Therapeutics AG $CRSP
Pictet Asset Management Holding SA reduced its stake in CRISPR Therapeutics AG by 13.0% in Q4 2025, selling 25,129 shares and now holding 167,464 shares valued at $9.02 million. Despite this, other institutional investors like JPMorgan Chase & Co. increased their holdings, and institutional ownership stands at 69.2%. Analysts have a "Moderate Buy" consensus with a price target of $64.53, while company insiders have been net sellers.
Assessing CRISPR Therapeutics (CRSP) Valuation After Casgevy Approval And CAR T Pipeline Progress
CRISPR Therapeutics (CRSP) has garnered attention following its regulatory approval for Casgevy and advancements in its CAR T pipeline. While the company's Price-to-Book ratio of 2.6x suggests fair value compared to peers, it is slightly higher than the broader biotech industry average. However, a Discounted Cash Flow model indicates the stock might be significantly undervalued at its current price of $51.63, projecting a fair value of $184.66, despite the company still being loss-making.
Is Early Casgevy Momentum Reframing CRISPR Therapeutics' (CRSP) Long-Term Profitability Narrative?
CRISPR Therapeutics (CRSP) is seeing increased investor attention due to expectations of higher revenue and earnings in its upcoming March-quarter report, driven by growing sales of its gene-editing therapy Casgevy. While strong Casgevy uptake with Vertex Pharmaceuticals brightens the near-term outlook for CRISPR's economic participation in a commercial product, the market remains cautious about the therapy's ability to offset the company's significant R&D spend, deep losses, and limited standalone sales from a largely preclinical pipeline. The article also notes a wide range in fair value estimates for CRSP shares, suggesting investor divergence on weighing Casgevy's success against execution and funding risks.
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Crispr Therapeutics AG (CRSP)
BMO Capital maintained a Buy rating for Eli Lilly & Co (LLY) with a price target of $1300.00, while TipRanks – xAI also upgraded the stock to Buy. Conversely, TD Cowen maintained a Hold rating for Crispr Therapeutics AG (CRSP) with a price target of $45.00, and TipRanks – xAI reiterated a Hold rating on CRSP. The article summarizes analyst ratings and price targets for these two healthcare companies, noting their current stock prices and analyst consensus.
UBS Group AG Boosts Stock Position in CRISPR Therapeutics AG $CRSP
UBS Group AG significantly increased its stake in CRISPR Therapeutics AG during the fourth quarter, growing its holdings by 7.7% to over 2.5 million shares valued at approximately $132.4 million. This increased institutional interest comes despite CRISPR Therapeutics missing quarterly earnings and revenue expectations, and a trend of insider selling. Analysts, however, maintain a "Moderate Buy" consensus rating for the company with an average price target of $64.53.
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know
CRISPR Therapeutics AG (CRSP) shares dipped by 2.59% in the latest trading session, underperforming the broader S&P 500. Despite the recent dip, the stock has gained 9.44% over the past month. Analysts project significant year-over-year increases in both EPS and revenue for the upcoming earnings report, with the company currently holding a Zacks Rank of #3 (Hold).
ARK, Catherine Wood disclose 11.79% stake in CRSP (CRSP)
ARK Investment Management LLC and Catherine D. Wood have disclosed an 11.79% beneficial ownership stake in CRISPR Therapeutics AG (CRSP), totaling 11,313,623 shares, according to an amended Schedule 13G/A filing. ARK holds sole voting power over 10,545,920 shares and sole dispositive power over the entire 11,313,623 shares. The filing, dated April 30, 2026, also notes that ARK Innovation ETF is a client holding more than 5% within ARK's client list.
Why the market dipped but CRISPR Therapeutics AG (CRSP) gained today
The article discusses why CRISPR Therapeutics AG (CRSP) experienced a gain in its stock price on a day when the broader market saw a dip. This suggests specific positive news or a favorable market perception for CRISPR that counteracted general negative trends.
CRISPR Therapeutics AG (CRSP) dips more than broader market: What you should know
This article from MSN reports that CRISPR Therapeutics AG (CRSP) experienced a stock dip that was greater than the broader market's decline. It suggests investors should be aware of this performance.
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know
CRISPR Therapeutics AG (CRSP) shares closed down 2.59% at $50.71, underperforming the broader S&P 500. Despite recent stock appreciation, analysts project a significant increase in upcoming earnings and revenue for the company, indicating a favorable long-term outlook. The stock currently holds a Zacks Rank of #3 (Hold), although its industry ranks in the bottom 40%.
CRISPR Therapeutics AG (CRSP) dips more than broader market: What you should know
CRISPR Therapeutics AG (CRSP) is reported to have experienced a stock dip, performing worse than the broader market. The article is likely to detail the extent of this underperformance and provide context for investors to understand the implications.
